Serum Institute of Life Sciences (SILS) has converted a $150 million loan into equity, increasing its investment in Biocon Biologics. This ...

Under the fresh terms of their strategic alliance, Serum Life Sciences will make an additional equity investment of $150 million through th...

Serum Institute of Life Sciences is a unit of Serum Institute of India, the world's biggest vaccine maker. Under new terms of the alliance,...

Biocon, incorporated in the year 1978, is a Large Cap company (having a market cap of Rs 28934.46 Crore) operating in Pharmaceuticals secto...

Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles. Over the past 25 years, he has helped build an...

To fund the upfront payment, Biocon Biologics has secured $1.2 billion of Sustainability Linked Loan (SLL). The balance has been funded thr...

The transaction with US-based Viatris required regulatory approvals from the Reserve Bank of India, Competition Commission of India and the...

Biocon Biologics in March entered into a definitive agreement to acquire Viatris' biosimilars assets for $3.34 billion. It will pay Viatris...

Once the deal is complete, Serum Institute Life Sciences Pvt Ltd will have about 15 per cent stake in Biocon Biologics Ltd, according to th...

Consolidated revenue from operations in the fourth quarter stood at Rs 2,408.8 crore as against Rs 1,842.1 crore in the year-ago period, it...

The $3.3-billion acquisition - that includes $2.3 billion cash and a 12.9% equity stake in BBL - stands at over half of the market cap of B...

Serum Life Sciences Ltd, a unit of India-based SII, will pick up a 3.9% stake in Oxford Biomedica as part of the deal. Oxford Biomedica, sp...

The Serum alliance would give Biocon Biologics' access to 100 million doses of vaccines per annum for 15 years with commercialisation right...

On Thursday, Biocon had said it will offer around 15 per cent stake to Serum Institute Life Sciences at a post-money valuation of about Rs3...

"The Biocon-Serum alliance will initially focus on Covid vaccines, because that is the need of the hour. At a later stage, we will see what...

The deal with Serum Institute Life Sciences values Biocon Biologics at about $4.9 billion and will solely focus on COVID-19 vaccines in the...

Under the alliance, BBL will get committed access to 100 million doses of vaccines annually for 15 years and commercialisation rights of th...